Sector portfolio · Private equity · United States

BC

Bain Capital Life Sciences' Biotech portfolio

Bain Capital Life Sciences has backed 32 Biotech startups in rounds we track, $7.8B between them, shown by the stage each has reached. The best-funded is Kymera Therapeutics.

32startups backed
4stages
$7.8Braised between them
Stage not reportedbiggest stage

Bain Capital Life Sciences's whole portfolioBain Capital Life Sciences's profile

Stage not reported

11

Series C and later

9

Series B

8

Series A

4

Segment by segment

Stage not reported

11 startups · $2.5B raised

  1. NuvalentNuvalent is a biopharmaceutical company that develops targeted therapies for cancer by designing small-molecule medicines.United States$500M
  2. New Amsterdam PharmaNew Amsterdam is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.Netherlands$453M
  3. Century TherapeuticsCentury Therapeutics is a biotechnology company that develops cell therapies for hematological and solid tumor malignancies.United States$385M
  4. Nurix TherapeuticsNurix Therapeutics is a biopharmaceutical company that focuses on the development and discovery of small molecule drugs.United States$250M
  5. Cabaletta BioCabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.United States$200M
  6. X4 PharmaceuticalsX4 Pharmaceuticals is a clinical-stage oncology company developing oral small molecule CXCR4 antagonists for the treatment.United States$193M
  7. Amylyx PharmaceuticalsAmylyx Pharmaceuticals specializes in providing solutions for Alzheimer’s and other diseases of the brain.United States$175M
  8. Replimune GroupReplimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer.United States$140M

Series C and later

9 startups · $2.9B raised

  1. Kymera TherapeuticsKymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.United States$799M
  2. ADC TherapeuticsADC Therapeutics develops antibody drug conjugates and non-antibody drug conjugate products.Switzerland$646M
  3. AdvanCellAdvanCell is radiopharmaceutical firm that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment.Australia$438M
  4. Solid BiosciencesSolid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.United States$333M
  5. Imperative CareImperative Care is a medical technology company based in Campbell, California, focused on developing innovations for patients withUnited States$196M
  6. CereVascCereVasc is a clinical-stage medical device company based in Boston, Massachusetts, focused on developing innovative, minimally inUnited States$155M
  7. Atsena TherapeuticsAtsena Therapeutics is a clinical-stage gene therapy company based in Durham, North Carolina, focused on developing treatments forUnited States$150M
  8. Jnana TherapeuticsJnana Therapeutics develops innovative therapies using a chemoproteomics drug discovery platform.United States$107M

Series B

8 startups · $2.0B raised

  1. Kailera TherapeuticsKailera Therapeutics develops next-generation injectable and oral therapies for chronic weight management.United States$600M
  2. SpringWorks TherapeuticsSpringWorks Therapeutics is a biopharmaceutical company that develops medicines for patients with severe rare diseases and cancer.United States$400M
  3. Cardurion PharmaceuticalsCardurion Pharmaceuticals is a clinical-stage biotechnology company founded in 2017, focused on developing innovative therapeuticsUnited States$260M
  4. Upstream BioUpstream Bio focuses on developing an antibody therapy for the treatment of severe asthma.United States$200M
  5. Kyverna TherapeuticsKyverna Therapeutics is pioneering a new class of therapies and cures for serious autoimmune diseases.United States$160M
  6. Alkeus PharmaceuticalsAlkeus Pharmaceuticals is a Boston-based startup focused on treatments for serious ophthalmic conditions.United States$150M
  7. PharvarisPharvaris is a clinical-stage biomedical company focused on bringing oral bradykinin B2-receptor antagonists to patients.Switzerland$132M
  8. AptinyxAptinyx Inc.United States$76M

Series A

4 startups · $368M raised

  1. Merida BiosciencesMerida Biosciences is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision medicines for autUnited States$121M
  2. AAavantiBioAavantiBio is a biopharmaceutical company that provides gene transfer and gene editing therapies to treat genetic diseases.-$107M
  3. Areteia TherapeuticsAreteia Therapeutics, Inc.United States$75M
  4. EEyebiotechEyebiotech is an ophthalmology biotechnology company that specializes in therapies for eye diseases.United States$65M

How this map is made. Every startup here works in Biotech and has raised money in a round we track that names Bain Capital Life Sciences as an investor. Each sits under the stage of its latest round. Rebuilt nightly; updated 15 November 2026.

More portfolio maps

All portfolios
Portfolio mapBain Capital Life Sciences portfolio map41 startups · $9.3BCo-investorsWho invests with Bain Capital Life Sciences36 co-investorsSector portfolioRA Capital Management's Biotech portfolio197 startups · $38BSector portfolioOrbiMed's Biotech portfolio176 startups · $28BSector portfolioPioneer Fund's AI portfolio171 startups · $2.8BSector portfolioGaingels' AI portfolio146 startups · $14B

Raising from investors like Bain Capital Life Sciences?

Find the investors who back startups like yours, with their cheques, rounds and partners, in the app with filters, lists and exports.

Find investorsMarket maps